Sign in

    Jaden Rismay • JPMorgan Chase & Co.

    Jaden Rismay is an Analyst at JPMorgan Chase & Co., specializing in equity research and data-driven market insights for institutional clients. While specific company coverage and performance metrics are not publicly available, Rismay contributes to sector analyses and supports the firm’s capital markets research capabilities. He began his professional career at JPMorgan and remains with the firm, focusing on delivering high-quality analytical support. Jaden Rismay holds the necessary professional credentials and securities registrations common to research analysts at top U.S. banks.

    Jaden Rismay's questions to Seer Inc (SEER) leadership

    Jaden Rismay's questions to Seer Inc (SEER) leadership • Q2 2025

    Question

    Jaden Rismay from JPMorgan Chase & Co. asked for more detail on the revenue contribution from the Thermo Fisher partnership and questioned how SEER's technology competes against established, targeted proteomic methods.

    Answer

    CFO David Horn stated that revenue from the Thermo Fisher partnership is currently "extremely modest" but is expected to increase in the second half of the year. CEO Omid Farokhzad added that the first revenue from the collaboration should be recognized in Q3 and that the opportunity pipeline is growing. Farokhzad positioned SEER as uniquely enabling deep, unbiased proteomics at scale, which he believes customers are increasingly choosing for discovery over the limited potential of targeted approaches, viewing the technologies as complementary.

    Ask Fintool Equity Research AI

    Jaden Rismay's questions to Seer Inc (SEER) leadership • Q3 2024

    Question

    Jaden Rismay of JPMorgan Chase & Co. asked for details on the anticipated impact of the new co-marketing collaboration with Thermo Fisher Scientific on Seer's market reach, customer base, and top-line revenue. He also inquired about the performance and traction of the Seer Technology Access Center (STAC) in Germany and the outlook for the service into 2025.

    Answer

    CEO Omid Farokhzad explained that the Thermo Fisher partnership, launching in Q1 2025, is timed well with the growing acceptance of the Proteograph's value. He expects it to expand reach and potentially shorten sales cycles by bundling with Thermo's Orbitrap Astral, particularly for customers analyzing biofluids like plasma. He noted that a more detailed revenue impact would be provided on the next earnings call. CFO & President David Horn added that the STAC program, both in the U.S. and the newly operationalized German lab, is seeing strong demand and steady growth. He reiterated its strategic value for seeding the market with data from key collaborators, sometimes at lower price points, to drive future publications and adoption.

    Ask Fintool Equity Research AI